Compare NOMA & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMA | BYSI |
|---|---|---|
| Founded | 2023 | 2010 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4M | 58.4M |
| IPO Year | N/A | 2016 |
| Metric | NOMA | BYSI |
|---|---|---|
| Price | $3.55 | $1.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.4K | ★ 14.4K |
| Earning Date | 05-22-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $1.18 |
| 52 Week High | $10.00 | $3.44 |
| Indicator | NOMA | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 52.88 |
| Support Level | $3.35 | $1.46 |
| Resistance Level | $4.69 | $1.75 |
| Average True Range (ATR) | 0.42 | 0.18 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 79.55 | 80.65 |
Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.